Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endralazine is a peripheral vasodilator developed as an antihypertensive agent for the treatment of essential hypertension. It acts by relaxing vascular smooth muscle, leading to decreased peripheral resistance and lower blood pressure. Clinical studies have shown that endralazine is effective in reducing blood pressure in patients with hypertension, including those whose condition was not controlled by beta-blockers and diuretics. Its side effect profile is similar to other hydrazine derivatives, with flushing being more common compared to dihydralazine. Unlike some related drugs (e.g., hydralazine), drug-induced lupus appears less frequent with endralazine[6][8]. Endralazine has been studied in both short-term and long-term settings for blood pressure control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endralazine.